About us_METiS TechBio

Dr. Chris Lai brings extensive cross-disciplinary experience spanning frontline scientific research and corporate strategic management, overseeing the R&D and strategic growth of METiS’ AI technology platforms.

He is a recipient of the MIT Innovation Award in Clean Energy and Water Treatment and the founder of AquaFresco, a pioneering water-tech company. Dr. Lai previously served as a strategic consultant at McKinsey & Company, advising leading global pharmaceutical companies.

Dr. Lai holds a Ph.D. in Chemical Engineering from the Novartis–MIT Center for Continuous Manufacturing.

Dr. Hongming Chen was elected a Member of the U.S. National Academy of Engineering in 2018 and is a veteran scientist in the field of drug delivery.

She leads METiS TechBio's R&D programs, guiding the team with relentless scientific passion and rigor.

She previously co-founded Kala Pharmaceuticals, leading the development of nanoparticle-based therapies through FDA approval and a successful IPO on NASDAQ. She also helped to establish TransForm Pharmaceuticals, which was later acquired by Johnson & Johnson.

Dr. Chen earned her Ph.D. at MIT under the mentorship of Bob Langer, MIT Institute Professor and widely regarded as the father of modern drug delivery.

Dr. Wenshou Wang leads the development of METiS TechBio's AI-driven drug formulation and delivery platforms and oversees day-to-day operations in China.

He has over 10 years of R&D experience in artificial intelligence, polymer synthesis, and innovative materials development, and previously served as a research scientist at the MIT Computer Science and Artificial Intelligence Lab (CSAIL).During that time, he developed the first machine learning-enabled 3D printer and subsequently co-founded Inkbit, an AI-powered 3D printing company.

Dr. Wang holds a Ph.D. in Polymer Chemistry from the Chinese Academy of Sciences and completed postdoctoral research in Chemistry at the University of Southern Mississippi and the University of Minnesota.

Dr. Wei Xu heads METiS’ Drug Discovery Department, responsible for advancing high-value mRNA-based therapeutic pipelines to the clinical stage.

Dr. Xu possesses a strong academic background and extensive industry experience across immunology, oncology, and cell therapy. Prior to joining METiS, he served as CSO at Numab Therapeutics (Switzerland), where he drove and executed the overall research strategy while managing the discovery, CMC, and translational medicine teams. Before Numab, he was Vice President and Head of New Drug Biology & Translational Medicine at Innovent Biologics (Suzhou), where he established the Guoqing Academy, building teams in research biology, translational medicine, and cell therapy. He was instrumental in establishing innovative drug discovery capabilities, moving from a “Me-too” to a FIC/BIC approach. His earlier industry training was highlighted by his seven-year tenure at Roche (USA/Switzerland) in immunology and oncology discovery divisions, where he led four pipelines from early discovery into clinical development.

Dr. Xu holds a Ph.D. in Immunology from Leiden University Medical Center (Netherlands) and completed his postdoctoral fellowship at the Baylor Institute for Immunology Research (USA).

Mark Herbert is responsible for driving METiS’ global business development and commercialization strategy.

Mark Herbert is a highly experienced executive with over 20 years of experience. Before joining METiS, he served as President at Arcturus, where he led deep collaboration with Johnson & Johnson, Takeda and CureVac on platform and mRNA pipeline collaborations, generating over $2 billion in partnership value. He also held roles as VP of Business Development at Varda Space Industries, Chief Business Officer at Scientists.com, and served on the boards of multiple biotech companies.

Mark Herbert holds a M.Sc. in Organic Chemistry from Indiana University.

Ms. Xie Wang has extensive experience in financial operations and is responsible for the Company’s overall financial management.

She has served as the financial director of the Company since joining the Company in 2021. Prior to that, she served as the financial controller in various companies and has over 20 years of experience in financial management, internal audit and treasury management.

Ms.Wang holds a master’s degree and is a member of the Association of Chartered Certified Accountants (ACCA) and a Chartered Professional Accountant in Canada.

Mr. Peng has extensive experience in capital operations and takes overall responsibility for investor relations management, information disclosure, public relations, investment and financing and capital market related matters. He works closely with the management team and the Board to enhance the Company’s communication with investors and the capital markets, supports the Company’s strategic development and capital operations, and continuously enhances the Company’s capital market influence, market recognition and long-term value creation capabilities.

Prior to joining the Company, Mr. Peng served as the company secretary and director of investor relations of Phancy Group Co., Ltd. (6682.HK), where he was deeply involved in the company’s capital market operations, responsible for investor relations management, corporate governance, regulatory compliance, information disclosure and financing projects, and maintained close communication and cooperation with global institutional investors.

Mr. Peng holds a Master’s degree in Finance from Warwick Business School and a Bachelor’s degree in Mathematics and Economics from the University of Warwick. He is also a Hong Kong Certified Public Accountant (HKICPA).